JBPHF (Jacobio Pharmaceuticals Group Co) Accounts Payable: $6.18 Mil (As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.34
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Accounts Payable?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Accounts Payable is $6.18 Mil as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.34. The stock has 6 warning signs investors should review.

Jacobio Pharmaceuticals Group Co's Accounts Payable for the quarter that ended in Dec. 2025 was $6.18 Mil.

Jacobio Pharmaceuticals Group Co's quarterly Accounts Payable declined from Dec. 2024 ($16.20 Mil) to Jun. 2025 ($9.24 Mil) and declined from Jun. 2025 ($9.24 Mil) to Dec. 2025 ($6.18 Mil).

Jacobio Pharmaceuticals Group Co's annual Accounts Payable increased from Dec. 2023 ($11.37 Mil) to Dec. 2024 ($16.20 Mil) but then declined from Dec. 2024 ($16.20 Mil) to Dec. 2025 ($6.18 Mil).

Jacobio Pharmaceuticals Group Co Accounts Payable Related Terms

Jacobio Pharmaceuticals Group Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Accounts Payable Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 8.02 13.85 11.37 16.20 6.18

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.37 10.89 16.20 9.24 6.18
JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $6.18 Mil mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Accounts Payable of $6.18 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Accounts Payable too high?
Jacobio Pharmaceuticals Group Co's current Accounts Payable is $6.18 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Accounts Payable compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Accounts Payable of $6.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Accounts Payable is $6.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Accounts Payable of $6.18 Mil. The stock's GF Value™ is $0.34, compared to a current price of $0.87 — trading 155.2% above its estimated fair value. The current Accounts Payable is $6.18 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Accounts Payable is $6.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 155.2% above its estimated GF Value™ of $0.34.

Key valuation signals for JBPHF:

  • Accounts Payable: $6.18 Mil
  • GF Value™: $0.34 vs. price of $0.87 (155.2% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.34
GF Value